



Executive Director Report September 2026

Licensing

License Type	Active	Detail	Renewal	Issued Last 30 Days
Pharmacist	24,342	Emeritus – 608		158
Pharmacy Intern	2,475			246
Pharmacy Technician	30,646	Trainee – 7,583 Registered – 7,647 Certified – 15,416 Active/Restricted – 771	Certified Tech – 7,901 (50%) Renewed	907
Terminal Distributor	22,623			133
Drug Distributor	2,356			15
Home Medical Equipment	794	License – 149 Registration – 645		9

***Counts as of 9/4/2026**

Compliance

STATISTICS – MAY 2026

In-Take Panel Statistics									
Cases Assigned	7/02	7/07	7/10	7/14	7/17	7/21	7/24	7/28	7/31
Consumer Complaint	4	7	7	2	2	8	4	2	7
Minimum Qualifications of TDDD/WDDD	2	3	1	1	6		7	3	4
Questionable Dispensing		1		1					
Working Conditions/Minimum Standards		1		1					
Error in Dispensing	1	4	3	3	1			4	
Illegal Processing of Drug Documents								1	1
Adulterated Drugs			1						
Deception to Obtain Dangerous Drugs	1		1			1			
Unprofessional Conduct/Gross Immorality	1	1	1		1	1			
Theft of Drugs		1							
Violation of Patient Confidentiality	1					1			1
Operating without a License	1				1	1			
Background Investigation			1						
OARRS Complaint							1		
Illegal Drug Sales		1		1	1				2
Abusing, Addicted, and/or Unfit			1		1				
Questionable Prescribing		1		1					
Drug Security		1						2	1
Trafficking in Drugs	2			1	1	3			1
Intelligence Information			1						
Failure to Perform DUR				1					
Compounding Violation				1					
Total	13	21	17	11	16	15	12	12	17

All Open Cases	New Cases Opened in Past 30 Days (July)	Number of Summary Suspensions in July	Cases Closed in Past 30 Days (July)
547	214	1	278

Top 10 Cases Opened in July 2026

Case Type	Cases Opened
Suspicious Purchases	34

Minimum Qualifications of TDDD/WDDD	30
Background Investigation	21
Error in Dispensing	19
Drug Security	17
Questionable Dispensing	11
Theft of Drugs	9
Trafficking in Drugs	9
Consumer Complaint	7
Late Renewal of TDDD/WDDD License	7

Investigations Summary (July)

Monthly Investigations Summary	Total
Current open cases (as of August 31, 2026)	547
Cases opened in July 2026	214
Complaints received	134
Cases opened from complaints (Intake)	82
Cases opened in the field (Self-Initiated)	29
Admin. cases referred to OBP Legal Department	46
Court orders received	1
Criminal convictions	1
Intervention in Lieu of Conviction (ILC)	2
Criminal indictments	4
Search warrants executed	1
Summary Suspensions	1
Monthly Inspection Summary	Total
Inspections completed	411
Written Response Required issued	142

Notable Investigative Events

- In July, the Board analyzed prescribing data and contributed to Overdose Fatality Review Committees in eight Ohio counties: Butler, Clark, Franklin, Hancock, Mahoning, Montgomery, Ross, and Stark.

Executive Director Report

FISCAL

FY26

Fund	Appropriation	Year-to-date Expenditures	Encumbered	Unexpended
OARRS Grants (3HD0)	\$ 2,094,643	\$ 1,514,967	\$ 20	\$ 579,656
Medicaid/OARRS Integration (3HH0)	\$ 642,117	\$ 609,433	\$ -	\$ 32,684
Equitable Sharing Treasury (3HM0)	\$ -	\$ 436	\$ -	\$ (436)
Equitable Sharing Justice (3HN0)	\$ -	\$ 7,842	\$ -	\$ (7,842)
Law Enforcement Fund (4A50)	\$ 50,000	\$ 10,947	\$ 1,125	\$ 37,928
Operating (4K90)	\$ 13,981,441	\$ 13,194,192	\$ 150,337	\$ 636,912
Drug Database Fund (5SG0)	\$ 2,826,000	\$ 2,573,912	\$ 13,720	\$ 238,368
All Funds Total	\$ 19,594,201	\$17,911,729	\$ 165,202	\$ 1,517,270

FY27

Fund	Appropriation	Year-to-date Expenditures	Encumbered	Unexpended
OARRS Grants (3HD0)	\$ 2,111,622.00	\$ 205,368	\$ -	\$ 1,906,254
Medicaid/OARRS Integration (3HH0)	\$ 645,729.00	\$ 23,442	\$ 471,048	\$ 151,239
Equitable Sharing Treasury (3HM0)	\$ -	\$ -	\$ -	\$ -
Equitable Sharing Justice (3HN0)	\$ -	\$ -	\$ -	\$ -
Law Enforcement Fund (4A50)	\$ 50,000	\$ 3,360	\$ -	\$ 46,640
Operating (4K90)	\$ 14,700,319	\$ 2,415,324	\$ 1,174,587	\$11,110,408
Drug Database Fund (5SG0)	\$ 2,865,000	\$ 75,700	\$ 1,683,781	\$ 1,105,519
All Funds Total	\$ 20,372,670	\$ 2,723,194	\$ 3,329,416	\$14,320,060

COMMUNICATIONS AND OUTREACH

- Executive Director Schierholt participated in the following:
 - Participated in NABP's Executive Committee Meeting
 - Attended IACP's webinar about AI situational awareness
 - Met with OPA's CEO
 - Held various other meetings with state agencies & leaders

Policy and Communications

HIGHLIGHTS

- HB12 DRUG PRACTICES-RIGHT TO TRY** (GROSS J, SWEARINGEN D) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 6/11/2025 – **BILL AMENDED**, House Health, (Sixth Hearing)
- HB192 PHARMACY ACCREDITATION, PBM REQUIREMENTS** (BARHORST T, FISCHER T) To limit insurer accreditation requirements for pharmacies, to implement drug cost reporting requirements for pharmacy benefit managers, and to name this act the Community Pharmacy Protection Act.
Current Status: 3/11/2026 - House Insurance, (Sixth Hearing)
- HB587 REGARDING KRATOM PRODUCT SALES** (ODIOSO M, LORENZ B) Regarding sales of kratom products.
Current Status: 3/18/2026 – House Agriculture, (Third Hearing)
- HB629 PRACTICE AUTHORIZATION-PHARMACISTS** (BARHORST T, GROSS J) To authorize pharmacists to treat minor health conditions and to name this act the Pharmacist Prescribing Authority Act.
Current Status: 3/11/2026 – House Health, (First Hearing)
- SB209 PATIENT RIGHT TO TRY ACT** (CUTRONA A, RENYOLDS M) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 5/28/2025 – Referred to Committee Senate Health
- SB230 AUTHORIZE PHARMACISTS-TREAT CERTAIN RESPIRATORY CONDITIONS** (ROMANCHUK M) Regarding prescribing, dispensing, and administering drugs and to name this act the Jeff, Dave, and Angie Patient Right to Try Act.
Current Status: 6/10/2026 – **PASSED BY SENATE**; Vote 31-2
- SB249 AUTHORIZE DISPENSING IVERMECTIN WITHOUT PRESCRIPTION** (LANG G, JOHNSON T) To authorize the dispensing of ivermectin without a prescription.
Current Status: 4/15/2026 – Senate Health, (Second Hearing)
- SB299 REGARDING KRATOM PRODUCT SALES** (BLESSING III L) Regarding sales of kratom products.
Current Status: 3/24/2026 - Senate General Government, (Second Hearing)